The miRNA-34a/Tat-A86 nanoformulation exhibited high suitability for miRNA-34a delivery to tumor sites by actively targeting IL-4R, a receptor highly expressed in most types of solid tumors. The gene discussed is TAT; the disease is neoplasm.